Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE:002399)

Market Cap	15.18B +1.4%
Revenue (ttm)	5.48B +3.8%
Net Income	349.49M -46.0%
EPS	0.24 -46.0%
Shares Out	1.47B
PE Ratio	47.82
Forward PE	19.31
Dividend	0.25 (2.19%)
Ex-Dividend Date	n/a

Volume	6,668,079
Average Volume	4,320,572
Open	11.53
Previous Close	11.39
Day's Range	11.34 - 11.73
52-Week Range	9.72 - 14.34
Beta	0.44
RSI	55.70
Earnings Date	Mar 30, 2026

About SHE:002399

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers finished dose pharmaceutical products, such as prolongin, inhixa, neoparin, and heparin and enoxaparin sodium injections; API products, including heparin and enoxaparin sodium APIs; and pan...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 1,926
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002399

Financial Performance

In 2025, SHE:002399's revenue was 5.48 billion, an increase of 4.18% compared to the previous year's 5.26 billion. Earnings were 349.49 million, a decrease of -45.96%.